Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (196)
  2. Journal Article (66)
  3. Review (14)
  4. Research Letter (9)
  5. Correspondence (4)
  6. Editorial (4)
  7. Guidelines (2)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (143)
  2. Department of Medicine (142)
  3. Center for Hematologic Malignancies (139)
  4. Myeloma (131)
  5. Graduate Medical Education (129)
  6. GME, Medicine (120)

More Groups

People
  1. Alexander Lesokhin (114)
  2. Kylee Maclachlan (109)
  3. Sham Mailankody (99)
  4. Urvi Shah (99)
  5. Carlyn Rose Tan (93)
  6. Malin Hultcrantz (91)

More People

Years
  1. 2025 (15)
  2. 2024 (75)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (86)
  2. Clinical Lymphoma, Myeloma and Leukemia (79)
  3. Journal of Clinical Oncology (30)
  4. Blood Cancer Journal (14)
  5. Blood Advances (13)
  6. Oncology Research and Treatment (7)

More Publications

Publishers
  1. American Society of Hematology (99)
  2. Elsevier Inc. (91)
  3. American Society of Clinical Oncology (30)
  4. Nature Publishing Group (20)
  5. Elsevier Science, Inc. (10)
  6. S. Karger AG (7)

More Publishers

Results (296)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comparative effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) for patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Krishnan, A.; Nooka, A.; Chari, A.; Garfall, A. L.; Martin, T.; Nair, S.; Lin, X.; Qi, K.; Londhe, A.; Pei, L.; more...
    Value in Health (2023)

    Fulltext@MSK | Save
  • Matching-adjusted indirect treatment comparison (MAIC) of teclistamab versus selinexor-dexamethasone for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Moreau, P.; Usmani, S. Z.; van de Donk, N. W. C. J.; Garfall, A. L.; Delforge, M.; Oriol, A.; Nooka, A.; Rosiñol, L.; Bahlis, N.; Rodriguez Otero, P.; more...
    Value in Health (2023)

    Fulltext@MSK | Save
  • Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs belantamab mafodotin for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Moreau, P.; Usmani, S. Z.; van de Donk, N. W. C. J.; Garfall, A. L.; Delforge, M.; Oriol, A.; Nooka, A.; Rosiñol, L.; Bahlis, N.; Otero, P. R.; more...
    Value in Health (2023)

    Fulltext@MSK | Save
  • Adjusted comparison of teclistamab versus real-world physician's choice (RWPC) of therapy in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Value in Health (2023)

    Fulltext@MSK | Save
  • Reversible Parkinsonism after BCMA-directed Car T cell administration
    Meeting Abstract

    Gewirtz, A.; Mailankody, S.; Usmani, S.; Santomasso, B.
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Real world outcomes with idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Sidana, S.; Ahmed, N.; Akhtar, O. S.; Heim, M.; Brazauskas, R.; Hansen, D. K.; Ferreri, C.; Freeman, C. L. L.; Afrough, A.; Anderson, L. D. Jr; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Unveiling the discrepancy in multiple myeloma risk classification between clinical practice and SKY92 test and the impact on survival
    Meeting Abstract

    Biran, N.; Dhakal, B.; Niesvizky, R.; Lentzsch, S.; McKay, J. T.; Vesole, D. H.; Nooka, A. K.; Paul, B.; Hari, P. N.; Stork-Sloots, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk newly diagnosed multiple myeloma (NDMM) with an inadequate response to frontline autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up
    Meeting Abstract

    Dhodapkar, M. V.; Alsina, M.; Berdeja, J. G.; Patel, K. K.; Richard, S.; Vij, R.; Leleu, X.; Egan, D. N.; Bergsagel, P. L.; Reshef, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of dexamethasone (Dex) dose strength on outcomes in newly diagnosed multiple myeloma (NDMM): A Secondary analysis of SWOG Studies S0777 and S1211
    Meeting Abstract

    Banerjee, R.; Sexton, R.; Cowan, A. J.; Ailawadhi, S.; Rajkumar, S. V.; Kumar, S. K.; Lonial, S.; Barlogie, B.; Durie, B. G. M.; Usmani, S. Z.; more...
    Blood (2023)

    Fulltext@MSK | Save